ArticleJAMA network open2021
Assessment of Global Trends in the Diagnosis of Mesothelioma From 1990 to 2017.
Article in JAMA network open, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed.
- Temporal trends, risk factors, and future projections of gastric cancer burden in China, India, and the United States: a GBD 2023 analysis.Discover oncology · 2026Article
- Trends in malignant mesothelioma incidence in Spain, 1999-2023: a joinpoint and age-period-cohort analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Dynamic evaluation of the glycolytic determinants LDH-A and GLUT-1 enhances prognostic significance and their inhibition affects the growth of mesothelioma spheroids.Molecular metabolism · 2026Article
- Diagnostic Challenges in Pleural Mesothelioma.Cancers · 2026Review
- Global Disability and Economic Burden Caused by Rheumatoid Arthritis, Osteoarthritis, Neck Pain, and Low Back Pain in Women of Childbearing Age from 1990 to 2021.International journal of women's health · 2026Article
- Burden and Trends of Crohn's Disease Among Women of Reproductive Age in China, India, and the United States, 1990-2023, with Projections to 2040: A Systematic Analysis for the Global Burden of Disease Study 2023.International journal of women's health · 2026Article
- Global bibliometric analysis of pleural mesothelioma biomarkers (2002-2024): trends and emerging frontiers.Journal of thoracic disease · 2025Article
- Demographic disparities in temporal trends and geographic variations of malignant pleural and peritoneal mesothelioma incidence in Pennsylvania, 1990-2019.Cancer causes & control : CCC · 2025Article
- Global burden of lung cancer attributable to occupational asbestos exposure: 1990 to 2021.Environmental health : a global access science source · 2025Article
- Article
- Pleural mesothelioma.Nature reviews. Disease primers · 2025Review
- HMGB1 as a Key Mediator in Malignant Mesothelioma and a Potential Target for Asbestos-Related Cancer Therapy.Toxics · 2025Article
- Incidence and Outcomes of Brain Metastasis in Pleural Mesothelioma in the Era of Immunotherapy.JTO clinical and research reports · 2025Article
- Molecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma.International journal of molecular sciences · 2025Review
- Burden of mesothelioma in the Middle East and North Africa: a 32-year analysis of the Global Burden of Diseases Study 2021.Annals of medicine and surgery (2012) · 2025Article
- Epidemiological trends and projections of esophageal cancer in BRICS-plus: Based on the GBD 2021 database.Frontiers in oncology · 2025Article
- Gene therapy for diffuse pleural mesotheliomas in preclinical models by concurrent expression of NF2 and SuperHippo.Cell reports. Medicine · 2024Article
- Immunotherapy for advanced and recurrent malignant pleural mesothelioma.The Cochrane database of systematic reviews · 2024Article
- Article
- Burden of malignant mesothelioma in China during 1990-2019 and the projections through 2029.Journal of the National Cancer Center · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: It is difficult for policy makers and clinicians to formulate targeted management strategies for mesothelioma because data on current epidemiological patterns worldwide are lacking. Objective: To evaluate the mesothelioma burden across the world and describe its epidemiological distribution over time and by sociodemographic index (SDI) level, geographic location, sex, and age. Design, Setting, and Participants: Annual case data and age-standardized rates of incidence, death, and disability-adjusted life-years associated with mesothelioma among different age groups were obtained from the Global Burden of Disease 2017 database. The estimated annual percentage changes in age-standardized rates were calculated to evaluate temporal trends in incidence and mortality. The study population comprised individuals from 21 regions in 195 countries and territories who were diagnosed with mesothelioma between 1990 and 2017. Data were collected from May 23, 2019, to January 18, 2020. Main Outcomes and Measures: Primary outcomes were incident cases, deaths, and their age-standardized rates and estimated annual percentage changes. Secondary outcomes were disability-adjusted life-years and relative temporal trends. Results: Overall, 34 615 new cases (95% uncertainty interval [UI], 33 530-35 697 cases) of mesothelioma and 29 909 deaths (95% UI, 29 134-30 613 deaths) associated with mesothelioma were identified in 2017, and more than 70% of these cases and deaths were among male individuals. In 1990, the number of incident cases was 21 224 (95% UI, 17 503-25 450), and the number of deaths associated with mesothelioma was 17 406 (95% UI, 14 495-20 660). These numbers increased worldwide from 1990 to 2017, with more than 50% of cases recorded in regions with high SDI levels, whereas the age-standardized incidence rate (from 0.52 [95% UI, 0.43-0.62] in 1990 to 0.44 [95% UI, 0.42-0.45] in 2017) and the age-standardized death rate (from 0.44 [95% UI, 0.37-0.52] in 1990 to 0.38 [95% UI, 0.37-0.39] in 2017) decreased, with estimated annual percentage changes of -0.61 (95% CI, -0.67 to -0.54) for age-standardized incidence rate and -0.44 (95% CI, -0.52 to -0.37) for age-standardized death rate. The proportion of incident cases among those 70 years or older continued to increase (from 36.49% in 1990 to 44.67% in 2017), but the proportion of patients younger than 50 years decreased (from 16.74% in 1990 to 13.75% in 2017) over time. In addition, mesothelioma incident cases and age-standardized incidence rates began to decrease after 20 years of a complete ban on asbestos use. For example, in Italy, a complete ban on asbestos went into effect in 1992; incident cases increased from 1409 individuals (95% UI, 1013-1733 individuals) in 1990, peaked in 2015 after 23 years of the asbestos ban, then decreased from 1820 individuals (95% UI, 1699-1981 individuals) in 2015 to 1746 individuals (95% UI, 1555-1955 individuals) in 2017. Conclusions and Relevance: This cross-sectional study found that incident cases of mesothelioma and deaths associated with mesothelioma continuously increased worldwide, especially in resource-limited regions with low SDI levels. Based on these findings, global governments and medical institutions may consider formulating optimal policies and strategies for the targeted prevention and management of mesothelioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.